Hypoplastisches myelodysplastisches Syndrom
- 20 October 2021
- journal article
- Published by Springer Science and Business Media LLC in InFo Hämatologie + Onkologie
- Vol. 24 (10), 22-25
- https://doi.org/10.1007/s15004-021-8811-7
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Treatment of low-risk myelodysplastic syndromesHematology, 2016
- Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)Oncotarget, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromesHaematologica, 2015
- Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population‐based data linkage studyCancer, 2014
- Immunologic Aspects of Hypoplastic Myelodysplastic SyndromeSeminars in Oncology, 2011
- Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA)Leukemia Research, 2010
- Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromesCancer, 2010
- The Epidemiology of Myelodysplastic SyndromesHematology/Oncology Clinics of North America, 2010
- Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approachHaematologica, 2009